Low risk for serious adverse events linked to common shoulder arthroscopy procedures; one in 26 at risk for reoperation at one year
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, July 14, 2022 (HealthDay News) -- The risk for serious adverse events associated with common shoulder arthroscopy procedures is low, according to a study published online July 6 in The BMJ.
Jonathan L. Rees, M.B.B.S., from the University of Oxford in the United Kingdom, and colleagues conducted a population-based cohort study involving 288,250 arthroscopic shoulder procedures performed in 261,248 patients aged 16 years and older between April 1, 2009, and March 31, 2017.
The researchers found that the overall rate of complications within 90 days after arthroscopic shoulder surgery, including reoperation, was 1.2 percent, with one in 81 patients at risk, and ranged by type of procedure from 0.6 to 1.7 percent for glenohumeral stabilization and frozen shoulder release, respectively. No effect of procedure type was seen after adjustment for age, comorbidities, and sex. The most common adverse event was pneumonia (0.3 percent), with one in 303 patients at risk. Pulmonary embolic events occurred in 0.1 percent, with one in 1,428 patients at risk. The overall rate for reoperation was 3.8 percent at one year, with one in 26 patients at risk, which varied from 2.7 to 5.7 percent for glenohumeral stabilization and frozen shoulder release, respectively. The number of arthroscopic procedures increased during the study period, apart from subacromial decompression, which decreased.
"As the numbers of other arthroscopic shoulder procedures continue to increase, this study provides real-world generalizable estimates of serious adverse events and reoperation rates that should better inform surgeons and patients," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry; one author has a patent issued.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on July 14, 2022
Read this Next
Other Trending Articles